Active	Status	Sponsor type	Region	Phase	Filter
10 Active 5 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gao, Shugeng
NCT05913089: A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer	Recruiting	2	58	RoW	TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Non Small Cell Lung Cancer	06/26	12/26
NCT04460066: A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.	Active, not recruiting	1/2	70	RoW	anti-PD-L1 antibody, ZKAB001, Socazolimab Injection, albumin bound paclitaxel, ABRAXANE, cisplatin, placebo, radical resection of esophageal carcinoma	Lee's Pharmaceutical Limited	Esophageal Cancer	12/21	07/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gao, Shugeng
NCT05913089: A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer	Recruiting	2	58	RoW	TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Non Small Cell Lung Cancer	06/26	12/26
NCT04460066: A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.	Active, not recruiting	1/2	70	RoW	anti-PD-L1 antibody, ZKAB001, Socazolimab Injection, albumin bound paclitaxel, ABRAXANE, cisplatin, placebo, radical resection of esophageal carcinoma	Lee's Pharmaceutical Limited	Esophageal Cancer	12/21	07/23